Alkem Laboratories Limited (ALKEM.NS)
INR 4887.45
(1.0%)
INR 4887.45
(1.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 126.67 Billion INR | 9.21% |
| 2022 | 115.99 Billion INR | 10.34% |
| 2021 | 105.12 Billion INR | 20.43% |
| 2020 | 87.28 Billion INR | 6.55% |
| 2019 | 81.91 Billion INR | 12.75% |
| 2018 | 72.65 Billion INR | 15.07% |
| 2017 | 63.14 Billion INR | 12.43% |
| 2016 | 56.16 Billion INR | 13.28% |
| 2015 | 49.57 Billion INR | 33.15% |
| 2014 | 37.23 Billion INR | 37.81% |
| 2013 | 27.01 Billion INR | 16.55% |
| 2012 | 23.18 Billion INR | 18.67% |
| 2011 | 19.53 Billion INR | 19.68% |
| 2010 | 16.32 Billion INR | 21.45% |
| 2009 | 13.43 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 30.31 Billion INR | 3.27% |
| 2023 Q1 | 29.67 Billion INR | 2.24% |
| 2023 Q2 | 34.4 Billion INR | 15.92% |
| 2023 Q4 | 29.35 Billion INR | -11.67% |
| 2023 FY | 126.67 Billion INR | 9.21% |
| 2023 Q3 | 33.23 Billion INR | -3.38% |
| 2022 Q2 | 30.79 Billion INR | 19.52% |
| 2022 Q3 | 30.4 Billion INR | -1.25% |
| 2022 Q1 | 25.76 Billion INR | 9.09% |
| 2022 FY | 115.99 Billion INR | 10.34% |
| 2022 Q4 | 29.02 Billion INR | -4.55% |
| 2021 Q3 | 26.18 Billion INR | -6.46% |
| 2021 FY | 105.12 Billion INR | 20.43% |
| 2021 Q4 | 23.61 Billion INR | -9.82% |
| 2021 Q2 | 27.99 Billion INR | 2.51% |
| 2021 Q1 | 27.31 Billion INR | 32.88% |
| 2020 Q1 | 20.03 Billion INR | 5.64% |
| 2020 FY | 87.28 Billion INR | 6.55% |
| 2020 Q2 | 23.62 Billion INR | 17.93% |
| 2020 Q4 | 20.55 Billion INR | -11.32% |
| 2020 Q3 | 23.18 Billion INR | -1.89% |
| 2019 Q3 | 21.81 Billion INR | -3.63% |
| 2019 FY | 81.91 Billion INR | 12.75% |
| 2019 Q4 | 18.96 Billion INR | -13.07% |
| 2019 Q1 | 18.49 Billion INR | 4.91% |
| 2019 Q2 | 22.64 Billion INR | 22.41% |
| 2018 FY | 72.65 Billion INR | 15.07% |
| 2018 Q4 | 17.62 Billion INR | -8.42% |
| 2018 Q3 | 19.25 Billion INR | 0.32% |
| 2018 Q2 | 19.18 Billion INR | 14.94% |
| 2018 Q1 | 16.69 Billion INR | 10.32% |
| 2017 Q1 | 12.95 Billion INR | 3.5% |
| 2017 FY | 63.14 Billion INR | 12.43% |
| 2017 Q4 | 15.13 Billion INR | -13.06% |
| 2017 Q3 | 17.4 Billion INR | -6.67% |
| 2017 Q2 | 18.64 Billion INR | 43.98% |
| 2016 FY | 56.16 Billion INR | 13.28% |
| 2016 Q2 | 16.15 Billion INR | 12.2% |
| 2016 Q1 | 14.39 Billion INR | 25.32% |
| 2016 Q4 | 12.51 Billion INR | -14.42% |
| 2016 Q3 | 14.62 Billion INR | -9.46% |
| 2015 Q4 | 11.48 Billion INR | -7.82% |
| 2015 Q1 | 11.96 Billion INR | 25.23% |
| 2015 FY | 49.57 Billion INR | 33.15% |
| 2015 Q3 | 12.45 Billion INR | -8.51% |
| 2015 Q2 | 13.61 Billion INR | 13.87% |
| 2014 Q4 | 9.55 Billion INR | -1.4% |
| 2014 Q3 | 9.68 Billion INR | 2.87% |
| 2014 Q2 | 9.41 Billion INR | 0.0% |
| 2014 Q1 | 9.41 Billion INR | 0.0% |
| 2014 FY | 37.23 Billion INR | 37.81% |
| 2013 FY | 27.01 Billion INR | 16.55% |
| 2012 FY | 23.18 Billion INR | 18.67% |
| 2011 FY | 19.53 Billion INR | 19.68% |
| 2010 FY | 16.32 Billion INR | 21.45% |
| 2009 FY | 13.43 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | -107.254% |
| Hester Biosciences Limited | 3.04 Billion INR | -4059.496% |
| Aarti Drugs Limited | 25.28 Billion INR | -400.977% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | -597.744% |
| Albert David Limited | 3.62 Billion INR | -3394.874% |
| Alembic Limited | 1.57 Billion INR | -7943.659% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -8208.479% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -2575.771% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -31541.027% |
| Brooks Laboratories Limited | 794.86 Million INR | -15836.849% |
| Eris Lifesciences Limited | 20.09 Billion INR | -530.497% |
| FDC Limited | 19.42 Billion INR | -551.979% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | -454.814% |
| Gufic Biosciences Limited | 8.06 Billion INR | -1470.363% |
| Hikal Limited | 17.84 Billion INR | -609.827% |
| Ind-Swift Limited | 5.02 Billion INR | -2421.071% |
| Innova Captab Limited | 10.81 Billion INR | -1071.509% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | -493.944% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -5969.697% |
| Jubilant Pharmova Limited | 67.02 Billion INR | -88.987% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | -2081.998% |
| Lupin Limited | 196.56 Billion INR | 35.555% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | -3348.334% |
| Medico Remedies Limited | 1.44 Billion INR | -8641.043% |
| Morepen Laboratories Limited | 17.01 Billion INR | -644.32% |
| Nectar Lifesciences Limited | 16.84 Billion INR | -651.977% |
| Orchid Pharma Limited | 8.19 Billion INR | -1446.018% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -1000.323% |
| RPG Life Sciences Limited | 5.82 Billion INR | -2076.373% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -8105.853% |
| Sigachi Industries Limited | 3.98 Billion INR | -3075.181% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -922.907% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -1104.883% |
| Themis Medicare Limited | 3.81 Billion INR | -3218.198% |
| Unichem Laboratories Limited | 16.57 Billion INR | -664.297% |
| Vaishali Pharma Limited | 862.79 Million INR | -14581.994% |
| Wanbury Limited | 5.75 Billion INR | -2100.571% |
| Windlas Biotech Limited | 6.3 Billion INR | -1907.68% |
| ZIM Laboratories Limited | 3.67 Billion INR | -3346.801% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -888.959% |
| Ipca Laboratories Limited | 77.05 Billion INR | -64.388% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 73.88% |
| Venus Remedies Limited | 5.91 Billion INR | -2041.785% |
| Sakar Healthcare Limited | 1.54 Billion INR | -8116.775% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 56.322% |
| Divi's Laboratories Limited | 78.45 Billion INR | -61.473% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -877.791% |
| Mankind Pharma Limited | 103.34 Billion INR | -22.572% |
| Sequent Scientific Limited | 13.69 Billion INR | -824.822% |
| Laurus Labs Limited | 50.01 Billion INR | -153.26% |
| Neuland Laboratories Limited | 15.58 Billion INR | -712.764% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | -267.424% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | -7.233% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 33.404% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -2907.28% |
| Wockhardt Limited | 27.89 Billion INR | -354.198% |
| Bal Pharma Limited | 3.39 Billion INR | -3634.33% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 54.623% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -1544.617% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -13145.009% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | -655.471% |
| Shilpa Medicare Limited | 11.53 Billion INR | -998.561% |
| Valiant Laboratories Limited | 1.82 Billion INR | -6858.022% |
| Ajanta Pharma Limited | 42.08 Billion INR | -200.985% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | -3101.973% |
| Granules India Limited | 45.06 Billion INR | -181.104% |
| Medicamen Biotech Limited | 1.79 Billion INR | -6964.775% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -4786.354% |
| Piramal Enterprises Limited | 60.33 Billion INR | -109.946% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | -19.444% |
| NATCO Pharma Limited | 40.02 Billion INR | -216.531% |
| Suven Life Sciences Limited | 116.92 Million INR | -108235.657% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -25023.37% |
| Strides Pharma Science Limited | 40.51 Billion INR | -212.693% |
| Indoco Remedies Limited | 18.17 Billion INR | -597.059% |
| Alpa Laboratories Limited | 1.08 Billion INR | -11549.528% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -12041.257% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -16668.191% |